News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Forum: Aktien User: Lirumlarum1

ImmunityBio pares gains following aldoxorubicin data in cancer https://seekingalpha.com/amp/news/3783723-immunitybio-pares-gains-following-aldoxorubicin-data-in-cancer

Ein weiterer Seeking Alpha Artikel https://seekingalpha.com/article/4476969-immunitybio-company-leaves-2021-on-a-high-note-share-price-still-falls-flat?source=copy_to_clipboard

https://www.google.com/amp/s/seekingalpha.com/amp/article/4472560-amyris-vaccine-upside Summary Amyris is the only synthetic biology company developing and manufacturing a portfolio of products at scale. Amyris has obtained access to differentiated vaccine technology through a licensing arrangement with the Infectious Disease Research Institute. Amyris has also partnered with ImmunityBio to gain access to RNA manufacturing capacity. ImmunityBio is developing COVID vaccines that have the potential to provide broader and longer lasting protection. Amyris is currently undervalued, even without considering the potential upside from a differentiated COVID vaccine.

CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer https://www.businesswire.com/news/home/20211221005233/en/CytRx-Highlights-ImmunityBios-Use-of-Aldoxorubicin-in-Ongoing-Clinical-Studies-for-Various-Forms-of-Cancer

“With the $300 million financing from NantCapital combined with the equity raised over the last nine months, we have made the decision to pause the At-the-Market offering and we are well positioned to further accelerate development of our oncology and COVID-19 trials— with the goal of bringing these promising technologies to more people in need globally.”

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing https://www.businesswire.com/news/home/20211220005286/en/

PSS: Nächste Woche startet Phase 3 in Afrika https://mobile.twitter.com/immunitybio/status/1471613689539153925

SEC Form 4: Sachs David C. converted options into 17,242 shares, increasing direct ownership by 65% to 43,700 units https://quantisnow.com/insight/2133072?s=s

Billionaire doctor Patrick Soon-Shiong's mission to place SA at forefront of the Covid fight https://www.news24.com/you/news/local/billionaire-doctor-patrick-soon-shiongs-mission-to-place-sa-at-forefront-of-the-covid-fight-20211126

40th Annual J.P. Morgan Health Care Conference JAN 10 - JAN 13, 2022 https://ir.immunitybio.com/events/event-details/40th-annual-jp-morgan-health-care-conference

ASCO® Gastrointestinal Cancers Symposium JAN 20 - JAN 21, 2022 https://ir.immunitybio.com/events/event-details/ascor-gastrointestinal-cancers-symposium

Video and full transcript of PSS' talk from this morning: https://mobile.twitter.com/gojadas/status/1468313654693175310?s=20

ImmunityBio Strikes Deals in Effort to Speed Development of Covid Vaccine https://labusinessjournal.com/news/2021/dec/06/immunitybio-strikes-deals-effort-speed-development/

Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination. https://www.google.com/amp/s/www.news-medical.net/amp/news/20211205/Preclinical-data-shows-enhanced-T-cell-responses-neutralization-of-SARS-CoV-2-variants-with-ImmunityBio-heterologous-vaccination.aspx